⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 3, 2024Open Access

Supplementary Figure S7 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (²²⁵Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S7. Distribution of 225Ac-pelgi and 225Ac-DOTA-pelgi in the MDA-PCa-2b prostate cancer CDX model.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schatz et al. (2024) studied this question.

synapsesocial.com/papers/68e66839b6db6435875f3d5f https://doi.org/10.1158/1078-0432.25956496.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S7 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer2024
2Supplementary Figure S2 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer2024
3Supplementary Figure S2 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer2024
4Supplementary Figure S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer2024
5Supplementary Figure S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (<sup>225</sup>Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer2024